Tumor lysis syndrome
Methodology & AI Transparency ⓘ
Tumor lysis syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Weight Management & Metabolic Syndrome practice, Tumor lysis syndrome (ICD-10 E88.3) is stratified through thyroid/cortisol exclusion [Tumor lysis syndrome E88.3], pairing targeted symptom control with longitudinal HOMA-IR Insulin Resistance in Tumor lysis syndrome (E88.3: Index) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code E88.3 categorizes Tumor lysis syndrome under Weight Management & Metabolic Syndrome.
- 3 Typical cash cost range: Clinicians assessing Tumor lysis syndrome focus on blunted endogenous GLP-1/PYY in Tumor lysis syndrome (E88.3: satiety hormone release) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Tumor lysis syndrome: Waist-to-Height Ratio [Tumor lysis syndrome E88.3] (< 0.50 (E88.3)) and HOMA-IR Insulin Resistance in Tumor lysis syndrome (E88.3: Index).
Ask our AI Specialists anything about Tumor lysis syndrome
What Is Tumor lysis syndrome?
Within Weight Management & Metabolic Syndrome practice, Tumor lysis syndrome (ICD-10 E88.3) is stratified through thyroid/cortisol exclusion [Tumor lysis syndrome E88.3], pairing targeted symptom control with longitudinal HOMA-IR Insulin Resistance in Tumor lysis syndrome (E88.3: Index) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Tumor lysis syndrome (ICD-10 E88.3) is driven by blunted endogenous GLP-1/PYY in Tumor lysis syndrome (E88.3: satiety hormone release); specialists in Weight Management & Metabolic Syndrome monitor HOMA-IR Insulin Resistance in Tumor lysis syndrome (E88.3: Index) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Tumor lysis syndrome (E88.3): co-existing blood pressure, in Tumor lysis syndrome (E88.3: triglyceride, or fasting)
- • Secondary Tumor lysis syndrome clinical sign: joint load discomfort in Tumor lysis syndrome (E88.3: in knees, hips,)
- • Symptom flares in Tumor lysis syndrome correlating with Waist-to-Height Ratio [Tumor lysis syndrome E88.3] deviation outside < 0.50 (E88.3)
- • Functional weight & metabolism impact requiring thyroid/cortisol exclusion [Tumor lysis syndrome E88.3] evaluation (E88.3)
Tumor lysis syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Tumor lysis syndrome E88.3] | < 0.50 (E88.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Tumor lysis syndrome (E88.3: Index) | < 1.4 (E88.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Tumor lysis syndrome (E88.3: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Tumor lysis syndrome
Treatment selection for Tumor lysis syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tumor lysis syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Coadministered Cagrilintide and Semaglutide in Adults with Overweight or: What a 3,417-Participant Study Found Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. The New England journal of medicine • 2025-08-14 • Phase III Randomized Trial | N = 3,417 | 96/100 | PMID 40544433 ↗ |
| New Insights on Benefits and safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor: What a 1,139-Participant Study Found Tofacitinib was efficacious in patients with UC regardless of prior TNFi failure status. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-03-15 • Phase III Randomized Trial | N = 1,139 | 96/100 | PMID 33684552 ↗ |
| New Insights on Benefits and safety of semaglutide compared with liraglutide and placebo for: What a 957-Participant Study Found In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses. Lancet (London, England) • 2018-08-25 • Randomized Controlled Trial | N = 957 | 93/100 | PMID 30122305 ↗ |
| New Insights on Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent: What a 381-Participant Study Found In patients with active RA who received ozoralizumab in combination with MTX, the signs and symptoms of RA were significantly reduced as compared with the outcomes in those receiving placebo. Arthritis & rheumatology (Hoboken, N.J.) • 2022-11-15 • Phase III Randomized Trial | N = 381 | 93/100 | PMID 35729713 ↗ |
| New Insights on Benefits and safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden: What a 258-Participant Study Found These updated data support therapeutic similarity of CT-P10 and rituximab and support the use of CT-P10 single-drug treatment for previously untreated LTBFL. Clinical lymphoma, myeloma & leukemia • 2022-02-15 • Phase III Randomized Trial | N = 258 | 93/100 | PMID 34686445 ↗ |
Tumor lysis syndrome Patient Community & “People Like Me” Threads
Filter Tumor lysis syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.